MedPath

Washington Cancer Institute Hematology-Oncology Associates, P.C.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

1

Active:0
Completed:1

Trial Phases

1 Phases

Phase 2:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 2
1 (100.0%)

Safety, Tolerability, and Treatment Effect of Belnacasan in Patients With COVID-19

Phase 2
Completed
Conditions
COVID-19
Interventions
Drug: Placebo
First Posted Date
2021-12-20
Last Posted Date
2022-11-23
Lead Sponsor
MedStar Health
Target Recruit Count
43
Registration Number
NCT05164120
Locations
🇺🇸

MedStar Washington Hospital Center, Washington, District of Columbia, United States

🇺🇸

MedStar Franklin Square, Baltimore, Maryland, United States

News

MedHub-AI Receives PMDA Approval for AI-Powered Coronary Assessment Technology in Japan

MedHub-AI's AutocathFFR® becomes the first fully automated AI-powered software to receive PMDA approval in Japan for calculating Fractional Flow Reserve values directly from X-ray angiograms without invasive procedures.

Blood Test Detects Early Liver Transplant Rejection Using Cell-Free DNA Analysis

Georgetown University and MedStar Health researchers developed a blood test that uses circulating cell-free DNA fragments to detect early signs of liver transplant rejection and complications.

Pharmacists Emerge as Critical Partners in Multiple Sclerosis B-Cell Therapy Management

Pharmacists are taking on expanded roles in shared decision-making for multiple sclerosis treatment, helping patients navigate complex B-cell therapies and improving treatment adherence.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.